
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3724984/publications.pdf Version: 2024-02-01



SEOK LINI KIM

#	Article	IF	CITATIONS
1	PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood, 2017, 129, 2437-2442.	1.4	399
2	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 2012, 120, 2973-2980.	1.4	361
3	A recurrent inactivating mutation in RHOA CTPase in angioimmunoblastic T cell lymphoma. Nature Genetics, 2014, 46, 371-375.	21.4	326
4	Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. Journal of Clinical Oncology, 2009, 27, 6027-6032.	1.6	312
5	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 389-400.	10.7	285
6	Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Research, 2018, 28, 1217-1227.	5.5	172
7	Expression of HIF-11±, CA IX, VECF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 2005, 49, 325-335.	2.0	159
8	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2013, 31, 2103-2109.	1.6	149
9	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget, 2015, 6, 17764-17776.	1.8	136
10	Type II enteropathyâ€associated Tâ€cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. American Journal of Hematology, 2012, 87, 663-668.	4.1	134
11	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood, 2011, 117, 1958-1965.	1.4	121
12	Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Annals of Hematology, 2014, 93, 1895-1901.	1.8	115
13	Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer, 2011, 11, 321.	2.6	107
14	Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer, 2013, 49, 3486-3496.	2.8	103
15	Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. European Journal of Cancer, 2012, 48, 3223-3231.	2.8	99
16	Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica, 2010, 95, 1935-1942.	3.5	95
17	Carbonic Anhydrase IX in Early-Stage Non–Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 7925-7933.	7.0	87
18	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematology,the, 2015, 2, e66-e74.	4.6	85

#	Article	IF	CITATIONS
19	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematology,the, 2020, 7, e284-e294.	4.6	78
20	Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. Korean Journal of Internal Medicine, 2015, 30, 496.	1.7	77
21	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1597-1604.	2.0	76
22	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica, 2016, 101, 757-763.	3.5	75
23	Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood, 2020, 136, 2754-2763.	1.4	74
24	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer, 2010, 10, 321.	2.6	73
25	Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. Journal of Hematology and Oncology, 2013, 6, 86.	17.0	67
26	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leukemia and Lymphoma, 2009, 50, 757-763.	1.3	63
27	Enteropathy-associated T-cell lymphoma—a clinicopathologic and array comparative genomic hybridization study. Human Pathology, 2010, 41, 1231-1237.	2.0	60
28	Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2008, 8, 237-240.	1.4	59
29	Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Annals of Hematology, 2015, 94, 71-78.	1.8	58
30	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i> . Oncotarget, 2017, 8, 17038-17049.	1.8	55
31	Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. Annals of Hematology, 2010, 89, 563-568.	1.8	54
32	Serum Vascular Endothelial Growth Factor per Platelet Count in Hepatocellular Carcinoma: Correlations with Clinical Parameters and Survival. Japanese Journal of Clinical Oncology, 2004, 34, 184-190.	1.3	53
33	Prognostic Value of Carbonic Anhydrase IX and Ki-67 Expression in Squamous Cell Carcinoma of the Tongue. Japanese Journal of Clinical Oncology, 2007, 37, 812-819.	1.3	53
34	Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Investigational New Drugs, 2013, 31, 469-472.	2.6	51
35	Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. Clinical Cancer Research, 2020, 26, 935-944.	7.0	51
36	Treatment of localized extranodal NK/T cell lymphoma, nasal type. International Journal of Hematology, 2010, 92, 690-696.	1.6	50

SEOK JIN KIM

#	Article	IF	CITATIONS
37	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Annals of Hematology, 2012, 91, 543-551.	1.8	50
38	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Annals of Hematology, 2011, 90, 1391-1398.	1.8	49
39	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncology, The, 2020, 21, 306-316.	10.7	49
40	Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population. Thrombosis Research, 2012, 130, e6-e12.	1.7	48
41	Matchedâ€pair analysis comparing the outcomes of primary breast and nodal diffuse large Bâ€cell lymphoma in patients treated with rituximab plus chemotherapy. International Journal of Cancer, 2012, 131, 235-243.	5.1	47
42	Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. Nutrition and Cancer, 2014, 66, 225-233.	2.0	47
43	A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica, 2015, 100, e505-e507.	3.5	43
44	Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. Journal of Hematology and Oncology, 2018, 11, 140.	17.0	43
45	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. Annals of Hematology, 2019, 98, 2541-2550.	1.8	43
46	Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leukemia and Lymphoma, 2006, 47, 1265-1273.	1.3	42
47	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34, 3413-3419.	7.2	42
48	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. American Journal of Hematology, 2012, 87, 937-940.	4.1	40
49	Isolation of Small Extracellular Vesicles From Human Serum Using a Combination of Ultracentrifugation With Polymer-Based Precipitation. Annals of Laboratory Medicine, 2020, 40, 253-258.	2.5	40
50	Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Quality of Life Research, 2010, 19, 1097-1103.	3.1	39
51	Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. Journal of Hematology and Oncology, 2011, 4, 34.	17.0	37
52	CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leukemia and Lymphoma, 2016, 57, 1413-1422.	1.3	37
53	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. Journal of Clinical Microbiology, 2018, 56, .	3.9	37
54	¹⁸ Fâ€FDG uptake and its clinical relevance in primary gastric lymphoma. Hematological Oncology, 2010, 28, 57-61.	1.7	36

#	Article	IF	CITATIONS
55	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. Annals of Hematology, 2016, 95, 325-335.	1.8	36
56	Brentuximab vedotin: clinical updates and practical guidance. Blood Research, 2017, 52, 243.	1.3	36
57	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget, 2016, 7, 85584-85591.	1.8	36
58	Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. American Journal of Hematology, 2003, 73, 263-266.	4.1	35
59	Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas. Acta Haematologica, 2008, 120, 211-216.	1.4	35
60	Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. International Journal of Hematology, 2013, 98, 346-354.	1.6	35
61	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. Journal of Infection, 2016, 73, 496-505.	3.3	34
62	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Modern Pathology, 2020, 33, 603-615.	5.5	34
63	The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. Journal of Hematology and Oncology, 2015, 8, 49.	17.0	33
64	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	1.8	33
65	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Modern Pathology, 2018, 31, 1418-1428.	5.5	33
66	Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leukemia and Lymphoma, 2012, 53, 1515-1524.	1.3	32
67	Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness. Mayo Clinic Proceedings, 2014, 89, 781-789.	3.0	31
68	Serum BAFF predicts prognosis better than APRIL in diffuse large B ell lymphoma patients treated with rituximab plus CHOP chemotherapy. European Journal of Haematology, 2008, 81, 177-184.	2.2	30
69	Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients. Japanese Journal of Clinical Oncology, 2010, 40, 1147-1153.	1.3	30
70	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leukemia and Lymphoma, 2015, 56, 1020-1026.	1.3	30
71	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. The Lancet Regional Health - Western Pacific, 2021, 10, 100126.	2.9	30
72	Real world experience of Râ€CHOP with or without consolidative radiotherapy vs DAâ€EPOCHâ€R in the firstâ€line treatment of primary mediastinal Bâ€cell lymphoma. Cancer Medicine, 2019, 8, 4626-4632.	2.8	29

#	Article	IF	CITATIONS
73	Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. Cancer Research and Treatment, 2016, 48, 312-321.	3.0	29
74	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR TAcells. Molecular Therapy, 2022, 30, 579-592.	8.2	29
75	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. Acta Haematologica, 2009, 122, 200-210.	1.4	28
76	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Medical Oncology, 2009, 26, 45-48.	2.5	28
77	Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Japanese Journal of Clinical Oncology, 2011, 41, 353-357.	1.3	28
78	Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. International Journal of Radiation Oncology Biology Physics, 2015, 93, 677-683.	0.8	28
79	l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. Journal of Hematology and Oncology, 2016, 9, 41.	17.0	28
80	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer, 2020, 20, 120.	2.6	27
81	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Annals of Hematology, 2011, 90, 539-546.	1.8	26
82	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment, 2020, 52, 374-387.	3.0	26
83	Human Placenta-Derived Feeders Support Prolonged Undifferentiated Propagation of a Human Embryonic Stem Cell Line, SNUhES3: Comparison with Human Bone Marrow-Derived Feeders. Stem Cells and Development, 2007, 16, 421-428.	2.1	25
84	Imaging Findings and Literature Review of 18F-FDG PET/CT in Primary Systemic AL Amyloidosis. Nuclear Medicine and Molecular Imaging, 2015, 49, 182-190.	1.0	25
85	The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leukemia Research, 2010, 34, 294-300.	0.8	24
86	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leukemia Research, 2010, 34, 1175-1179.	0.8	24
87	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer, 2016, 16, 613.	2.6	24
88	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2471-2478.	2.0	24
89	A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Annals of Hematology, 2020, 99, 2095-2104.	1.8	24
90	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. Acta Haematologica, 2014, 131, 193-199.	1.4	23

#	Article	IF	CITATIONS
91	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. Oncotarget, 2015, 6, 42803-42812.	1.8	23
92	Serum level of <scp>CXCL10</scp> is associated with inflammatory prognostic biomarkers in patients with diffuse large <scp>B</scp> â€cell lymphoma. Hematological Oncology, 2017, 35, 480-486.	1.7	23
93	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine, 2020, 161, 105853.	2.9	23
94	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget, 2017, 8, 76231-76240.	1.8	23
95	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. International Journal of Hematology, 2010, 91, 456-463.	1.6	22
96	Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. Leukemia and Lymphoma, 2019, 60, 2237-2246.	1.3	22
97	Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-ήB and Btk. Oncotarget, 2017, 8, 5361-5370.	1.8	22
98	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Annals of Hematology, 2009, 88, 1099-1106.	1.8	21
99	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. Leukemia and Lymphoma, 2009, 50, 1119-1125.	1.3	21
100	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. International Journal of Hematology, 2011, 93, 383-388.	1.6	21
101	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e548-e561.	10.7	21
102	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 261-266.	3.0	21
103	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver International, 2015, 35, 2363-2369.	3.9	21
104	Impact of fear of cancer recurrence on survival among lymphoma patients. Psycho-Oncology, 2020, 29, 364-372.	2.3	21
105	Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. Experimental Hematology and Oncology, 2021, 10, 33.	5.0	21
106	FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 2466-2476.	1.8	21
107	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. Nutrition, 2017, 36, 67-71.	2.4	20
108	PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Scientific Reports, 2020, 10, 12641.	3.3	20

#	Article	IF	CITATIONS
109	Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. Cancer Research and Treatment, 2018, 50, 1051-1063.	3.0	20
110	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2006, 57, 436-442.	2.3	19
111	B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy. Leukemia and Lymphoma, 2012, 53, 19-25.	1.3	19
112	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. Annals of Hematology, 2014, 93, 437-447.	1.8	19
113	Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly. Current Opinion in Oncology, 2015, 27, 392-398.	2.4	19
114	The t(11;14)(q13;q32) Translocation as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 227-235.	0.4	19
115	Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma. Cancer Research and Treatment, 2018, 50, 575-581.	3.0	19
116	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. Anticancer Research, 2018, 38, 3935-3942.	1.1	19
117	Hematopoietic Differentiation of Embryoid Bodies Derived from the Human Embryonic Stem Cell Line SNUhES3 in Co-culture with Human Bone Marrow Stromal Cells. Yonsei Medical Journal, 2005, 46, 693.	2.2	18
118	Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. Leukemia and Lymphoma, 2011, 52, 205-213.	1.3	18
119	Isolation of Side Population Cells in B-Cell Non-HodgkinÂ's Lymphomas. Acta Haematologica, 2013, 129, 10-17.	1.4	18
120	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. BioMed Research International, 2014, 2014, 1-11.	1.9	18
121	Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life. Annals of Hematology, 2017, 96, 739-747.	1.8	18
122	Early disease progression in patients with localized natural killer/Tâ€cell lymphoma treated with concurrent chemoradiotherapy. Cancer Science, 2018, 109, 2056-2062.	3.9	18
123	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer, 2020, 20, 803.	2.6	18
124	Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia. Japanese Journal of Clinical Oncology, 2007, 37, 382-384.	1.3	17
125	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Investigational New Drugs, 2012, 30, 368-375.	2.6	17
126	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. Acta Haematologica, 2014, 131, 18-27.	1.4	17

#	Article	IF	CITATIONS
127	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer, 2019, 19, 1080.	2.6	17
128	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. Journal of Hematology and Oncology, 2020, 13, 21.	17.0	17
129	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood, 2020, 136, 2548-2556.	1.4	17
130	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget, 2017, 8, 13782-13791.	1.8	17
131	Clonal relationships in recurrent B-cell lymphomas. Oncotarget, 2016, 7, 12359-12371.	1.8	17
132	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. Korean Journal of Internal Medicine, 2017, 32, 890-899.	1.7	17
133	Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease – Consortium for Improving Survival of Lymphoma Study. Acta Haematologica, 2012, 127, 100-104.	1.4	16
134	Unmet needs of nonâ€Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with healthâ€related quality of life. Psycho-Oncology, 2017, 26, 330-336.	2.3	16
135	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Annals of Hematology, 2018, 97, 1437-1443.	1.8	16
136	Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/Tâ \in ell lymphoma. Cancer Science, 2018, 109, 3971-3980.	3.9	16
137	A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study. Scientific Reports, 2019, 9, 14961.	3.3	16
138	Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis. Scientific Reports, 2019, 9, 7746.	3.3	16
139	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. Cancers, 2020, 12, 2192.	3.7	16
140	Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia, 2021, 35, 1356-1364.	7.2	16
141	Autocrine Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for the Cyclooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells. Oncology, 2005, 68, 204-211.	1.9	15
142	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Medical Oncology, 2010, 27, 91-97.	2.5	15
143	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. Acta Haematologica, 2010, 123, 48-54.	1.4	15
144	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Research, 2015, 50, 242.	1.3	15

#	Article	IF	CITATIONS
145	Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. Annals of Hematology, 2020, 99, 1293-1302.	1.8	15
146	Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis. Journal of Cancer, 2021, 12, 2825-2834.	2.5	15
147	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. Annals of Hematology, 2012, 91, 1747-1756.	1.8	14
148	Clinical features and treatment outcome of Epstein–Barr virus-positive nodal T-cell lymphoma. International Journal of Hematology, 2016, 104, 591-595.	1.6	14
149	Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. Hematological Oncology, 2017, 35, 310-316.	1.7	14
150	Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 1341-1348.	1.3	14
151	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. Journal of Cancer, 2017, 8, 1018-1024.	2.5	14
152	CXCR4 can induce PI3K \hat{I} inhibitor resistance in ABC DLBCL. Blood Cancer Journal, 2018, 8, 23.	6.2	14
153	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. Bone Marrow Transplantation, 2018, 53, 967-976.	2.4	14
154	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. Blood Advances, 2020, 4, 868-879.	5.2	14
155	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget, 2016, 7, 72033-72043.	1.8	14
156	Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue. Cancer Research and Treatment, 2007, 39, 109.	3.0	14
157	Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. Cancer Research and Treatment, 2015, 47, 448-457.	3.0	14
158	Validation of the Korean Version of the Quality of Life–Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors. Cancer Research and Treatment, 2018, 50, 204-211.	3.0	14
159	Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 617-625.	1.8	13
160	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. Annals of Hematology, 2018, 97, 2363-2372.	1.8	13
161	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1205-1208.	2.4	13
162	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 628807.	2.8	13

#	Article	IF	CITATIONS
163	The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Research, 2015, 35, 2465-74.	1.1	13
164	Unusual Presentation of Ewing Sarcoma in the Adrenal Gland: A Secondary Malignancy from a Survivor of Burkitt Lymphoma. Japanese Journal of Clinical Oncology, 2013, 43, 676-680.	1.3	12
165	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. OncoTargets and Therapy, 2014, 7, 1717.	2.0	12
166	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. British Journal of Haematology, 2018, 181, 707-710.	2.5	12
167	Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma. Leukemia and Lymphoma, 2019, 60, 317-325.	1.3	12
168	Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Communications, 2019, 39, 1-10.	9.2	12
169	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Scientific Reports, 2019, 9, 20302.	3.3	12
170	Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. Cancers, 2020, 12, 3548.	3.7	12
171	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	1.8	12
172	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 92171-92182.	1.8	12
173	A Case of Non-Hodgkin`s Lymphoma in a patient with Neurofibromatosis Type 1. Korean Journal of Internal Medicine, 2003, 18, 202-205.	1.7	12
174	Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. Leukemia and Lymphoma, 2012, 53, 173-175.	1.3	11
175	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Annals of Hematology, 2012, 91, 223-233.	1.8	11
176	Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica, 2015, 100, e106-e109.	3.5	11
177	KIR alloreactivity based on the receptor–ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. Human Immunology, 2015, 76, 636-643.	2.4	11
178	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Research, 2016, 51, 181.	1.3	11
179	Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. Annals of Hematology, 2016, 95, 581-591.	1.8	11
180	Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. Cytokine, 2019, 113, 371-379.	3.2	11

#	Article	IF	CITATIONS
181	Validation of the Marginal Zone Lymphoma International Prognostic Index. Annals of Hematology, 2019, 98, 457-464.	1.8	11

99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis. Medicine (United) Tj ETQq0 $\stackrel{0.0}{1.0}$ rgBT $\stackrel{0.0}{1.0}$ rg

183	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. International Journal of Heart Failure, 2020, 2, 231.	2.7	11
184	Relapsed or refractory nongastric marginal zone Bâ€cell lymphoma: Multicenter retrospective analysis of 92 cases. American Journal of Hematology, 2009, 84, 826-829.	4.1	10
185	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. Annals of Hematology, 2010, 89, 1011-1018.	1.8	10
186	Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Investigational New Drugs, 2010, 28, 171-177.	2.6	10
187	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. Blood Research, 2014, 49, 107.	1.3	10
188	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemotherapy and Pharmacology, 2016, 77, 865-873.	2.3	10
189	Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. Annals of Hematology, 2018, 97, 1427-1436.	1.8	10
190	Prognostic values of novel biomarkers in patients with AL amyloidosis. Scientific Reports, 2019, 9, 12200.	3.3	10
191	A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. Frontiers in Oncology, 2021, 11, 696147.	2.8	10
192	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Research and Treatment, 2015, 47, 173-181.	3.0	10
193	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. Anticancer Research, 2014, 34, 4299-306.	1.1	10
194	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 27-33.	2.3	9
195	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. Investigational New Drugs, 2013, 31, 1514-1521.	2.6	9
196	Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients. Supportive Care in Cancer, 2014, 22, 2669-2675.	2.2	9
197	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Research. 2017. 52. 200.	1.3	9
198	Singleâ€dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. Journal of Clinical Apheresis, 2019, 34, 579-588.	1.3	9

SEOK JIN КІМ

#	Article	IF	CITATIONS
199	Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean. Journal of Global Oncology, 2019, 5, 1-10.	0.5	9
200	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWPâ€164) Tj ETQq0)004.ngBT	/Overlock 10 1
201	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Medicine, 2020, 17, e1003091.	8.4	9
202	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels. Cancer Research and Treatment, 2021, 53, 847-856.	3.0	9
203	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. BMC Cancer, 2021, 21, 82.	2.6	9
204	Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein. Cancer Research and Treatment, 2014, 46, 307-311.	3.0	9
205	Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma. Cancer Research and Treatment, 2019, 51, 547-555.	3.0	9
206	Stage IV marginal zone B ell lymphoma – prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Science, 2010, 101, 2443-2447.	3.9	8
207	Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?. The Korean Journal of Hematology, 2012, 47, 202.	0.7	8
208	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2274-2284.	6.4	8
209	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Investigational New Drugs, 2020, 38, 1472-1482.	2.6	8
210	Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Cytokine, 2020, 129, 155048.	3.2	8
211	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Annals of Hematology, 2020. 99. 1283-1291.	1.8	8
212	Comparison of firstâ€line treatments of peripheral Tâ€cell lymphoma according to regimen: A systematic review and metaâ€analysis. Hematological Oncology, 2021, 39, 664-673.	1.7	8
213	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. Korean Journal of Internal Medicine, 2020, 35, 946-956.	1.7	8
214	Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma. Blood, 2014, 124, 2523-2523.	1.4	8
215	Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: Does it have a prognostic value?. Leukemia and Lymphoma, 2008, 49, 1623-1626.	1.3	7
216	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. Leukemia and Lymphoma, 2009, 50, 1110-1118.	1.3	7

#	Article	IF	CITATIONS
217	Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma. Acta Haematologica, 2015, 133, 179-182.	1.4	7
218	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. Oncotarget, 2016, 7, 47127-47133.	1.8	7
219	Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. Blood Cancer Journal, 2017, 7, 653.	6.2	7
220	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. International Journal of Hematology, 2019, 110, 438-446.	1.6	7
221	Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis. Annals of Laboratory Medicine, 2019, 39, 430-437.	2.5	7
222	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016. Medicine (United States), 2019, 98, e17641.	1.0	7
223	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 731-740.	1.2	7
224	Primary Follicular Lymphoma in a Male Breast: A Case Report. Cancer Research and Treatment, 2014, 46, 104-107.	3.0	7
225	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea Blood, 2009, 114, 5024-5024.	1.4	7
226	Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation. Acta Haematologica, 2014, 132, 226-232.	1.4	6
227	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. International Journal of Hematology, 2015, 102, 678-688.	1.6	6
228	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research, 2016, 51, 193.	1.3	6
229	Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. Acta Haematologica, 2016, 136, 186-190.	1.4	6
230	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Leukemia Research, 2017, 57, 1-8.	0.8	6
231	Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood Research, 2017, 52, 193.	1.3	6
232	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. Annals of Hematology, 2020, 99, 223-228.	1.8	6
233	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. Scientific Reports, 2020, 10, 11649.	3.3	6
234	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. Patient Education and Counseling, 2020, 103, 1630-1636.	2.2	6

#	Article	IF	CITATIONS
235	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization. BMC Cancer, 2020, 20, 619.	2.6	6
236	Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. Frontiers in Oncology, 2021, 11, 669817.	2.8	6
237	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer, 2021, 21, 972.	2.6	6
238	Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma. Cancer Management and Research, 2021, Volume 13, 7289-7297.	1.9	6
239	High-Dose Cytarabine Consolidation (≥1.5 g/m2) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m2) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen. Blood, 2013, 122, 2692-2692.	1.4	6
240	Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. Oncotarget, 2016, 7, 68350-68359.	1.8	6
241	Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Research and Treatment, 2019, 51, 1302-1312.	3.0	6
242	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. Blood Cancer Journal, 2021, 11, 200.	6.2	6
243	Mesenchymal Stem Cells Derived from Human Chorionic Plate May Promote Hematopoietic Differentiation of the Human Embryonic Stem Cell Line SNUhES3. Acta Haematologica, 2006, 116, 219-222.	1.4	5
244	Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). International Journal of Hematology, 2012, 96, 631-637.	1.6	5
245	Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 204-211.	3.0	5
246	Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Research, 2013, 48, 72.	1.3	5
247	Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. BioMed Research International, 2014, 2014, 1-7.	1.9	5
248	Spinal cord compression in multiple myeloma: a single center experience. Leukemia and Lymphoma, 2014, 55, 2395-2397.	1.3	5
249	A subset of CD45+/CD19 â^' cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. Leukemia and Lymphoma, 2015, 56, 3052-3057.	1.3	5
250	Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Annals of Laboratory Medicine, 2016, 36, 209-214.	2.5	5
251	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. Japanese Journal of Clinical Oncology, 2017, 47, 995-1001.	1.3	5
252	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investigational New Drugs, 2018, 36, 877-885.	2.6	5

SEOK JIN KIM

#	Article	IF	CITATIONS
253	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. Annals of Hematology, 2018, 97, 1851-1857.	1.8	5
254	Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping. Scientific Reports, 2021, 11, 5879.	3.3	5
255	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. Cancer Research and Treatment, 2021, , .	3.0	5
256	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood, 2014, 124, 4443-4443.	1.4	5
257	tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method. Analytical Chemistry, 2021, 93, 14088-14098.	6.5	5
258	Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. Annals of Laboratory Medicine, 2022, 42, 558-565.	2.5	5
259	Lymphoma stem cells: A step toward a new therapeutic target. The Korean Journal of Hematology, 2011, 46, 211.	0.7	4
260	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. Annals of Hematology, 2016, 95, 911-919.	1.8	4
261	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia and Lymphoma, 2016, 57, 1406-1412.	1.3	4
262	Realâ€world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Communications, 2021, 41, 275-278.	9.2	4
263	EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. Scientific Reports, 2021, 11, 10342.	3.3	4
264	Role of 23.4ÂGy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. Journal of Neuro-Oncology, 2021, 154, 207-217.	2.9	4
265	Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis. ESC Heart Failure, 2021, , .	3.1	4
266	Recent advances in understanding and managing T-cell lymphoma. F1000Research, 2017, 6, 2123.	1.6	4
267	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. Cancer Research and Treatment, 2017, 49, 92-103.	3.0	4
268	Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. Leukemia and Lymphoma, 2021, , 1-7.	1.3	4
269	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. Journal of Cancer, 2022, 13, 1388-1397.	2.5	4
270	Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. Cancer Research and Treatment, 2023, 55, 291-303.	3.0	4

#	Article	IF	CITATIONS
271	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. Cancer Research and Treatment, 2021, , .	3.0	4
272	Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma Journal of Clinical Oncology, 2022, 40, 7522-7522.	1.6	4
273	Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy. Korean Journal of Internal Medicine, 2003, 18, 125-128.	1.7	3
274	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leukemia and Lymphoma, 2011, 52, 317-320.	1.3	3
275	Dexamethasone, methotrexate, ifosfamide,l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. Leukemia and Lymphoma, 2014, 55, 2196-2198.	1.3	3
276	Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea. Blood Research, 2015, 50, 187.	1.3	3
277	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. Blood Research, 2015, 50, 160.	1.3	3
278	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. International Journal of Hematology, 2015, 102, 420-425.	1.6	3
279	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. Annals of Hematology, 2020, 99, 255-264.	1.8	3
280	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. Blood Advances, 2020, 4, 5762-5771.	5.2	3
281	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with nonâ€Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Transplant International, 2020, 33, 1211-1219.	1.6	3
282	Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. Journal of Cancer, 2021, 12, 2488-2497.	2.5	3
283	Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. Scientific Reports, 2021, 11, 9243.	3.3	3
284	Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. Cancer Management and Research, 2021, Volume 13, 4241-4250.	1.9	3
285	Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study. Blood Research, 2020, 55, 85-90.	1.3	3
286	Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. Journal of Neuro-Oncology, 2022, 156, 307-316.	2.9	3
287	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK. Cancer Research and Treatment, 2023, 55, 314-324.	3.0	3
288	CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. Blood Advances, 2022, 6, 6120-6130.	5.2	3

SEOK JIN KIM

#	Article	IF	CITATIONS
289	Mantle cell lymphoma: a model for risk-adapted treatment approach. Blood Research, 2014, 49, 1.	1.3	2
290	Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/Tâ€cell lymphoma, nasal type. International Forum of Allergy and Rhinology, 2015, 5, 960-966.	2.8	2
291	Mycobacterium abscessus glossitis. Lancet Infectious Diseases, The, 2017, 17, 1098.	9.1	2
292	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2051-2059.	2.4	2
293	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. Korean Journal of Internal Medicine, 2021, 36, 668-678.	1.7	2
294	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric <scp>CD34</scp> ⁺ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. Journal of Clinical Apheresis, 2021, 36, 737-749.	1.3	2
295	A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review. Annals of Laboratory Medicine, 2021, 41, 593-597.	2.5	2
296	Myelomatous Pleural Effusion of Multiple Myeloma: Characteristics and Outcome Blood, 2009, 114, 3874-3874.	1.4	2
297	Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2013, 122, 3037-3037.	1.4	2
298	A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2014, 124, 5465-5465.	1.4	2
299	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology, 2012, 30, 8023-8023.	1.6	2
300	Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis. Annals of Laboratory Medicine, 2020, 40, 409-413.	2.5	2
301	Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. Korean Journal of Internal Medicine, 2016, 31, 560-569.	1.7	2
302	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. British Journal of Haematology, 2022, 196, 1117-1120.	2.5	2
303	Prognostic Significance of Ki-67 Expression in Extranodal NK/T Cell Lymphoma, Nasal Type: A Proposed Prognostic Index, KLABS Index Blood, 2006, 108, 2055-2055.	1.4	2
304	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. PLoS ONE, 2018, 13, e0192656.	2.5	2
305	Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. Bone Marrow Transplantation, 2022, 57, 641-648.	2.4	2
306	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Research and Treatment, 2023, 55, 325-333.	3.0	2

SEOK JIN KIM

#	Article	IF	CITATIONS
307	Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. Annals of Hematology, 0, , .	1.8	2
308	Reply to K. Shimada et al. Journal of Clinical Oncology, 2010, 28, e230-e230.	1.6	1
309	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. Annals of Laboratory Medicine, 2020, 40, 88-91.	2.5	1
310	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. Supportive Care in Cancer, 2021, 29, 4969-4977.	2.2	1
311	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. International Journal of Hematology, 2021, 114, 355-362.	1.6	1
312	Obesity-Independent Association between Glycemic Status and the Risk of Hematologic Malignancy: A Nationwide Population-Based Longitudinal Cohort Study. Cancers, 2021, 13, 4760.	3.7	1
313	Detection of Extracellular Protein Kinase A (ECPKA) Autoantibody in Non-Hodgkin's Lymphoma: Its Increased Antibody Titer Decreases with a Favorable Treatment Response Blood, 2006, 108, 4621-4621.	1.4	1
314	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotying in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study Blood, 2009, 114, 4902-4902.	1.4	1
315	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients Blood, 2009, 114, 4956-4956.	1.4	1
316	Peripheral Blood Eosinophilia: An Unusual Presentation of Bone Marrow Involvement in a Patient with Relapsed Thyroid Papillary Carcinoma. The Korean Journal of Hematology, 2005, 40, 274.	0.7	1
317	Evaluation of biochemichal features of anemia in cancer patients Journal of Clinical Oncology, 2014, 32, e20698-e20698.	1.6	1
318	Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab. Korean Journal of Medicine, 2017, 92, 415-418.	0.3	1
319	Development of Lower Extremity Lymphedema Nursing Practice Protocol for Patients Following Gynecologic Cancer Treatment. Asian Oncology Nursing, 2018, 18, 143.	0.6	1
320	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. Blood, 2019, 134, 2227-2227.	1.4	1
321	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Korean Journal of Internal Medicine, 2020, 35, 194-204.	1.7	1
322	Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis. Blood Research, 2021, , .	1.3	1
323	Comprehensive Understanding of Gut Microbiota in Treatment NaÃ⁻ve Diffuse Large B Cell Lymphoma Patients. Blood, 2021, 138, 2409-2409.	1.4	1
324	Prediction of the breakthrough cancer pain using deep learning model Journal of Clinical Oncology, 2021, 39, e24085-e24085.	1.6	0

SEOK JIN КІМ

#	Article	IF	CITATIONS
325	Does Real-time Compound Imaging Improve Evaluation of Breast Cancer Compared to Conventional Sonography?. Journal of Korean Breast Cancer Society, 2002, 5, 102.	0.1	0
326	The Cutoff Value of Serum Ferritin for the Diagnosis of Iron Deficiency in the Community-Residing Older Persons Blood, 2004, 104, 5291-5291.	1.4	0
327	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells Blood, 2004, 104, 4201-4201.	1.4	0
328	Prediction of Survival in Patients with Non-Hodgkin's Lymphoma: Role of Tumor Necrosis Factor Ligand-Receptor and Extracellular Protein Kinase A Blood, 2005, 106, 4737-4737.	1.4	0
329	Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institue Experience in Korea Blood, 2005, 106, 2682-2682.	1.4	0
330	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. The Korean Journal of Hematology, 2007, 42, 335.	0.7	0
331	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma Blood, 2007, 110, 3446-3446.	1.4	0
332	Serum B-Cell Activating Factor (BAFF) in Diffuse Large B-Cell Lymphoma: Its Prognostic Significance in the Rituximab Era Blood, 2007, 110, 1575-1575.	1.4	0
333	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients Blood, 2007, 110, 4843-4843.	1.4	0
334	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. Blood, 2008, 112, 4219-4219.	1.4	0
335	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases Blood, 2009, 114, 4661-4661.	1.4	0
336	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. Blood, 2010, 116, 5084-5084.	1.4	0
337	The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort Study. Blood, 2012, 120, 5095-5095.	1.4	0
338	The Clinical Significance Of Activated p-AKT Expression In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 4315-4315.	1.4	0
339	The Distinct Stem Cell Population Derived From Chorionic Plate Of Human Placenta Which Has Differentiation Potential Into Erythroid Lineage Cells. Blood, 2013, 122, 4843-4843.	1.4	0
340	Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP Chemotherapy. Blood, 2013, 122, 5103-5103.	1.4	0
341	Extranodal NK/T-Cell Lymphoma, Nasal Type. , 2014, , 121-131.		0
342	Clinical Relevance of CD45+/CD19- Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center Experience. Blood, 2014, 124, 1622-1622.	1.4	0

#	Article	IF	CITATIONS
343	Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2015, 126, 3942-3942.	1.4	0
344	Dyadic Concordance of Sexuality Among Hematopoietic Stem Cell Transplantation Patients and Their Partners. Blood, 2015, 126, 4349-4349.	1.4	0
345	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. Blood, 2015, 126, 4889-4889.	1.4	0
346	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. Blood, 2015, 126, 1904-1904.	1.4	0
347	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. Blood, 2015, 126, 5160-5160.	1.4	0
348	Clinical utility of comprehensive approach to detect genetic abnormalities in multiple myeloma Journal of Clinical Oncology, 2016, 34, 8034-8034.	1.6	0
349	Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. Blood, 2016, 128, 4650-4650.	1.4	0
350	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. Blood, 2016, 128, 3041-3041.	1.4	0
351	Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. Blood, 2019, 134, 4002-4002.	1.4	0
352	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. Blood, 2019, 134, 2847-2847.	1.4	0
353	Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center. Blood, 2019, 134, 5585-5585.	1.4	0
354	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. Archives of Medical Science, 0, , .	0.9	0
355	Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-7.	3.0	0